The amount of additional consideration based on net sales of product as defined under a collaboration agreement.

No definition available.

Name:	fgen_AdditionalConsiderationBasedOnNetSales
Namespace Prefix:	fgen_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of aggregate consideration receivable under collaborative arrangement.

+ References

No definition available.

+ Details

Name:	fgen_CollaborativeArrangementAggregateConsideration
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the amount of milestone payments related to commercial sales under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	fgen_CommercialSalesMilestone
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	fgen_DevelopmentAndRegulatoryApprovalMilestones
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Estimated joint development extended service period.

+ References

No definition available.

+ Details

Name:	fgen_EstimatedJointDevelopmentExtendedServicePeriod
Namespace Prefix:	fgen_
Data Type:	xbrli:gYearItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs.

+ References

No definition available.

+ Details

Name:	fgen_PercentageOfFundingForCosts
Namespace Prefix:	fgen_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	fgen_PotentialMilestones
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration.

+ References

No definition available.

+ Details

Name:	fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Transaction price allocated to performance obligations.

+ References

No definition available.

+ Details

Name:	fgen_TransactionPriceAllocatedToPerformanceObligations
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

+ Details

Name:	us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)(7)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765

+ Details

Name:	us-gaap_Supplies
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended				3 Months Ended	12 Months Ended	35 Months Ended	45 Months Ended
	Nov. 30, 2018	Sep. 30, 2019	Dec. 31, 2018	Apr. 30, 2006	Jun. 30, 2005	Jun. 30, 2018	Dec. 31, 2019	Feb. 28, 2009	Feb. 28, 2009
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Unbilled contract asset			$ 0				$ 180,000
Europe [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Unbilled contract asset							$ 130,000
Astellas Agreement [Member] \| Japan [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront, non-contingent and time-based payments received									$ 40,100
Potential milestone payments		$ 12,500			$ 132,500
Commercial sales milestone					15,000
Additional consideration based on net sales description							low 20% range
Aggregate consideration received							$ 90,100
Transaction price and allocated to performance obligations		$ 12,500
Consideration associated with milestone included in transaction price						$ 15,000
Contract with customer, liability, revenue recognized			$ 43,900			$ 20,900
Difference in estimated and actual listed price	$ 36,300						$ 36,300
Astellas Agreement [Member] \| Japan [Member] \| Clinical and Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments					22,500
Astellas Agreement [Member] \| Japan [Member] \| Regulatory Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments					$ 95,000
Astellas Agreement [Member] \| Europe [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront, non-contingent and time-based payments received								$ 320,000
Additional consideration based on net sales description							low 20% range
Aggregate consideration received							$ 410,000
Transaction price and allocated to performance obligations							130,000
Development and regulatory approval milestones				$ 425,000
Percentage of joint development costs committed to fund				50.00%
Revenue during period from performance obligations							128,800
Unbilled contract asset							$ 130,000
Estimated joint development extended service period							2023
Astellas Agreement [Member] \| Europe [Member] \| Clinical and Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments				$ 90,000
Astellas Agreement [Member] \| Europe [Member] \| Regulatory Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments				$ 335,000